Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Strategy Inc. (MSTR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Strategy Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $220.93 (market cap $29.60B), while Strategy Inc. trades at $97.66 (market cap $37.84B). The key difference: Strategy Inc. is the larger of the two by market cap. Which is the better fit depends on your goals.
| ALNY | MSTR | |
|---|---|---|
Market Cap | $29.60B | $37.84B |
Sector | Health | Technology |
52-Week High | $491.22 | $394.39 |
52-Week Low | $205.48 | $82.31 |
Enterprise Value | $27.56B | $56.61B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Strategy Inc.
MicroStrategy Inc is a provider of enterprise analytics and mobility software. It offers MicroStrategy Analytics platform that delivers reports and dashboards and enables users to conduct ad hoc analysis and share insights through mobile devices or the Web
Read more on MSTR →
